# **Special Issue**

# Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances

# Message from the Guest Editor

According to the World Health Organization, of the four most prevalent infectious diseases, the incidences of tuberculosis, malaria, and human immunodeficiency virus are declining (the former two since 1990; the third since 2005), and only hepatitis B and C (HBV and HCV, respectively) are continuing to rise in their incidence. These two viruses can cause severe liver fibrosis as well as hepatocellular carcinoma (HCC). More recently, steatotic liver disease (SLD) has also become a major cause of HCC with and without cirrhosis. There are major developments in the treatment of these diseases.

## **Guest Editor**

Prof. Dr. Ching-Lung Lai Faculty Of Medicine, University of Hong Kong, Hong Kong, China

# Deadline for manuscript submissions

25 September 2025



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/202568

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





# **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

